Blockchain Registration Transaction Record

Silo Pharma Secures USPTO Allowance for PTSD Therapeutic SPC-15

Silo Pharma gets USPTO Notice of Allowance for SPC-15, an intranasal PTSD therapy. This patent boosts its IP portfolio and advances development.

This patent allowance is a significant milestone for Silo Pharma and the PTSD treatment landscape. PTSD affects millions worldwide, and current therapies often have limited efficacy or undesirable side effects. By securing U.S. patent protection for SPC-15, Silo Pharma strengthens its intellectual property position, which could attract investors and partners, accelerating the development of a novel intranasal treatment. The allowance also complements the earlier Japanese patent, signaling global recognition of the innovation. For patients, this progress offers hope for a new therapeutic option that targets stress-induced fear and anxiety. Moreover, it underscores the importance of protecting proprietary research in the competitive biopharmaceutical industry, potentially paving the way for further advancements in CNS disorders.